Recurium IP Holdings LLC has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) binding moiety covalently linked to a Wee1-like protein kinase (Wee1)-targeting moiety via a linker reported to be useful for the treatment of cancer.
Researchers from Beigene (Beijing) Co. Ltd. have disclosed preclinical data for BGB-B167, a first-in-class immunoglobulin G (IgG)-based bispecific antibody (bsAb) targeting 4-1BB and CEA, being developed for the treatment of advanced or metastatic solid tumors.
Insilico Medicine Inc. recently discussed the generative artificial intelligence (AI)-powered design of ISM-6331, a novel, potent, selective and non-covalent pan-TEAD inhibitor that blocks TEAD palmitoylation to suppress YAP/TAZ-TEAD transcriptional activity and shows strong antitumor activity in a preclinical model of Hippo pathway-dysregulated cancers and other solid cancers were discussed.
The U.S. FDA has cleared Biocity Biopharma Co. Ltd.’s IND application for a phase I study of BC-2027. This is the company’s second first-in-class antibody-drug conjugate (ADC) to be approved for clinical trials, following BC-3195, which is directed against placental-cadherin (CDH3).
DXC-006 (Hangzhou DAC Biotechnology Co. Ltd.) is an antibody-drug conjugate (ADC) that targets CD56, a molecule involved in cell-cell adhesion and cell-matrix adhesion that is overexpressed in neuroblastoma, small-cell lung cancer and multiple myeloma, but less frequently expressed in normal tissues. DXC-006 consists of an anti-CD56 antibody (DXA-006) linked to the topoisomerase 1 (TOP1) inhibitor CPT-116 through a linker.
The discovery of a potent, selective and orally bioavailable serine/threonine-protein kinase PLK4 (STK18) inhibitor with synthetic lethality in TRIM7-amplified cancers was reported by Oric Pharmaceuticals Inc. at the ongoing AACR meeting in San Diego.
Researchers from Puhe Biopharma Co. Ltd. presented the discovery and preclinical evaluation of PH027-1, a novel small-molecule Werner syndrome protein (WRN) inhibitor targeting microsatellite instability high (MSI-H) tumors.
Prior to this year’s Annual Meeting of the American Association for Cancer Research (AACR), it had been 14 years since metastasis had been the subject of a plenary session. So, the Tuesday session on “Evolution of the genome, microenvironment, and host through metastasis” had plenty of new insights to share.
Stable disease in about half the patients tested wasn’t enough for Wall Street, and shares of Vincerx Pharma Inc. (NASDAQ:VINC) nosedived by $3.72, or 78%, to close April 9 at $1.06 on the disclosure of preliminary phase I data with small-molecule drug conjugate VIP-236 in metastatic solid tumors.
Essential Pharma Ltd. is paying up to £70 million (US$88.7 million) to acquire Renaissance Pharma Ltd., taking ownership of Hu14.18, a treatment for high-risk neuroblastoma. The antibody has completed a 64-patient phase II trial conducted by St Jude’s Children’s Research Hospital, in which it showed an improvement in overall survival of around 50% compared to currently available therapies.